IBT
BBIO icon

International Biotechnology Trust’s BridgeBio Pharma BBIO Stock Holding History

International Biotechnology Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-52,800
Closed -$881K – 71
2021
Q4 		$881K Buy
+52,800
New +$2.23M 0.2% 59

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

International Biotechnology Trust's BBIO Position: Q1 2022 in Review

International Biotechnology Trust sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 52,800 shares — an estimated $881K sold.

International Biotechnology Trust first reported a position in BBIO in Q4 2021 and held it in 1 quarter. The position peaked at $881K in Q4 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • International Biotechnology Trust reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • International Biotechnology Trust sold 52,800 BridgeBio Pharma shares in Q1 2022, an estimated $881K.
  • International Biotechnology Trust first reported a position in BridgeBio Pharma in Q4 2021 and held it in 1 quarter.
  • International Biotechnology Trust's BridgeBio Pharma position peaked at $881K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on International Biotechnology Trust's 13F filing for Q1 2022, filed 20 May 2022.